◎ Sugi Atlas

Atlas / Gene / ENGASE

ENGASE

gene
On this page

Also known as FLJ21865

Summary

ENGASE (endo-beta-N-acetylglucosaminidase, HGNC:24622) is a protein-coding gene on chromosome 17q25.3, encoding Cytosolic endo-beta-N-acetylglucosaminidase (Q8NFI3). Endoglycosidase that releases N-glycans from glycoproteins by cleaving the beta-1,4-glycosidic bond in the N,N’-diacetylchitobiose core.

This gene encodes a cytosolic enzyme which catalyzes the hydrolysis of peptides and proteins with mannose modifications to produce free oligosaccharides.

Source: NCBI Gene 64772 — RefSeq curated summary.

At a glance

  • GWAS associations: 2
  • Clinical variants (ClinVar): 171 total
  • Druggable target: yes — 5 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_001042573

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:24622
Approved symbolENGASE
Nameendo-beta-N-acetylglucosaminidase
Location17q25.3
Locus typegene with protein product
StatusApproved
AliasesFLJ21865
Ensembl geneENSG00000167280
Ensembl biotypeprotein_coding
OMIM611898
Entrez64772

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 7 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000300682, ENST00000311595, ENST00000577783, ENST00000578419, ENST00000579016, ENST00000579809, ENST00000583041, ENST00000583646, ENST00000584568, ENST00000585160, ENST00000903610, ENST00000903611, ENST00000903612, ENST00000945017, ENST00000945018

RefSeq mRNA: 5 — MANE Select: NM_001042573 NM_001042573, NM_001396052, NM_001396053, NM_001396054, NM_001396055

CCDS: CCDS42394

Canonical transcript exons

ENST00000579016 — 14 exons

ExonStartEnd
ENSE000011117137907948979079637
ENSE000011117307908189879082063
ENSE000034752817907766379077864
ENSE000034968227908523479085342
ENSE000035368647908302079083123
ENSE000035979027908376179083951
ENSE000036035487908593379088599
ENSE000036077737908092579081073
ENSE000036222197908562079085734
ENSE000036462667908348279083590
ENSE000036512507908020779080364
ENSE000036584487908453879084686
ENSE000036726287907743079077497
ENSE000039022927907482479075090

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 95.77.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.9937 / max 885.0759, expressed in 1803 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter IDTPM avgSamples expressed
16317121.75661803
1631701.9611562
1631720.276079

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
mucosa of transverse colonUBERON:000499195.77gold quality
spleenUBERON:000210695.41gold quality
transverse colonUBERON:000115795.13gold quality
small intestine Peyer’s patchUBERON:000345495.09gold quality
granulocyteCL:000009494.85gold quality
pancreatic ductal cellCL:000207994.55silver quality
tendon of biceps brachiiUBERON:000818894.11gold quality
sural nerveUBERON:001548894.11gold quality
small intestineUBERON:000210894.09gold quality
right lobe of thyroid glandUBERON:000111993.56gold quality
left ovaryUBERON:000211993.54gold quality
right ovaryUBERON:000211893.45gold quality
body of stomachUBERON:000116193.37gold quality
apex of heartUBERON:000209893.29gold quality
right uterine tubeUBERON:000130293.09gold quality
endocervixUBERON:000045892.94gold quality
right adrenal glandUBERON:000123392.94gold quality
left uterine tubeUBERON:000130392.77gold quality
right adrenal gland cortexUBERON:003582792.65gold quality
left adrenal gland cortexUBERON:003582592.51gold quality
gastrocnemiusUBERON:000138892.50gold quality
left lobe of thyroid glandUBERON:000112092.38gold quality
esophagogastric junction muscularis propriaUBERON:003584192.28gold quality
muscle of legUBERON:000138392.24gold quality
muscle layer of sigmoid colonUBERON:003580592.24gold quality
body of uterusUBERON:000985392.23gold quality
right atrium auricular regionUBERON:000663192.22gold quality
metanephros cortexUBERON:001053392.22gold quality
thyroid glandUBERON:000204692.16gold quality
left adrenal glandUBERON:000123492.13gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3yes4.98
E-MTAB-6386no789.75

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 10)

  • involved in processing of free oligosaccharides in the cytosol; identification of the gene encoding human cytosolic ENGase (PMID:12114544)
  • endo-beta-n-acetylglucosaminidase present in the synovial fluid of rheumatoid arthritis patients, may contribute to the depletion of glycosaminoglycans from cartilage allowing the invasion of synovial cells (PMID:12905469)
  • identification of O-GlcNAcase as a caspase-3 substrate with a novel caspase-3 cleavage site and provide insight about O-GlcNAcase regulation during apoptosis. (PMID:18586680)
  • Data show that kinetic and X-ray crystallographic analyses of the binding modes with human/bacterial O-GlcNAcases identify some of these as competitive inhibitors. (PMID:20026047)
  • O-GlcNAcase expression is increased in erythrocytes from both individuals with pre-diabetes and individuals with less well-controlled diabetes. (PMID:20413512)
  • As the generation of the bulk of fOS is unaffected by co-down regulation of Ngly1p and Engase1p, alternative quantitatively important mechanisms must underlie the liberation of these fOS from either LLO or glycoproteins during protein N-glycosylation. (PMID:20668520)
  • Serological N-acetyl-glucosaminidase, telomere length, and the UCP2-886G>A variant are independent risk factors for type 2 diabetes. (PMID:21873561)
  • In patients with autosomal dominant polycystic kidney disease, urinary NAGase was correlated with urinary ET-1 which was inversely associated with eGFR and positively correlated with total kidney volume. (PMID:26923419)
  • Transcriptome-wide association study reveals two genes that influence mismatch negativity. (PMID:33730571)
  • N-acetyl-ss-D-glucosaminidase is predictive of mortality in chronic heart failure: a 10-year follow-up. (PMID:34397265)

Cross-species orthologs

5 orthologs

OrganismSymbolGene ID
danio_rerioengaseENSDARG00000010035
mus_musculusEngaseENSMUSG00000033857
rattus_norvegicusEngaseENSRNOG00000027498
drosophila_melanogasterENGaseFBGN0030839
caenorhabditis_elegansWBGENE00017164

Protein

Protein identifiers

Cytosolic endo-beta-N-acetylglucosaminidase — Q8NFI3 (reviewed: Q8NFI3)

All UniProt accessions (4): Q8NFI3, F8W925, J3QLG5, J9JID0

UniProt curated annotations — full annotation on UniProt →

Function. Endoglycosidase that releases N-glycans from glycoproteins by cleaving the beta-1,4-glycosidic bond in the N,N’-diacetylchitobiose core. Involved in the processing of free oligosaccharides in the cytosol.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Widely expressed. Expressed at higher level in thymus and spleen.

Similarity. Belongs to the glycosyl hydrolase 85 family.

Isoforms (3)

UniProt IDNamesCanonical?
Q8NFI3-11yes
Q8NFI3-22
Q8NFI3-33

RefSeq proteins (5): NP_001036038, NP_001382981, NP_001382982, NP_001382983, NP_001382984 (=MANE)

Domains & families (InterPro)

IDNameType
IPR001357BRCT_domDomain
IPR005201TIM_ENGaseDomain
IPR032979ENGaseFamily
IPR057882ENGase_CDomain

Pfam: PF03644, PF25529

Enzyme classification (BRENDA):

  • EC 3.2.1.96 — mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (BRENDA: 59 organisms, 331 substrates, 58 inhibitors, 37 Km, 16 kcat entries)

Substrate kinetics (BRENDA)

25 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
4-NITROPHENYL-BETA-D-N-ACETYLGLUCOSAMINE3.5–77.45
DANSYL ASIALOTRANSFERRIN GLYCOPEPTIDE0.68–22
DANSYL-ASN-(GLCNAC)2(MAN)50.207–0.8762
FMOC-ASN(FUCALPHA(1->6)GLCNAC)-OH8.51–18.512
FMOC-ASN(GLCNAC)-OH0.73–5.222
MAN3GLCNAC-OXAZOLINE0.5–0.672
(MAN)5(GLCNAC)2-PYRIDYLAMINO0.41
(MAN)5(GLCNAC)2ASN-ACETYL0.21
(MAN)6(GLCNAC)2-PYRIDYLAMIDATED0.0251
(MAN)6(GLCNAC)2-PYRIDYLAMINO0.251
(MAN)9(GLCNAC)2-PYRIDYLAMINO0.321
4-METHYLUMBELLIFERYL DI-N-ACETYL-BETA-CHITOBIOSI0.00631
4-METHYLUMBELLIFERYL N,N’,N’’-TRIACETYL-BETA-D-G0.02041
9-FLUORENYLMETHYLOXYCARBONYL-LABELED ASPARAGINE-5.541
ASN(GLCNAC)2-(MAN)50.251

Catalyzed reactions (Rhea), 1 shown:

  • an N(4)-(oligosaccharide-(1->3)-[oligosaccharide-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc)-L-asparaginyl-[protein] + H2O = an oligosaccharide-(1->3)-[oligosaccharide-(1->6)]-beta-D-Man-(1->4)-D-GlcNAc + N(4)-(N-acetyl-beta-D-glucosaminyl)-L-asparaginyl-[protein] (RHEA:73067)

UniProt features (14 total): splice variant 4, sequence variant 2, sequence conflict 2, modified residue 2, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q8NFI3-F186.410.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 1, 66

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

IDPathway
R-HSA-532668N-glycan trimming in the ER and Calnexin/Calreticulin cycle

MSigDB gene sets: 94 (showing top): GOBP_N_GLYCAN_PROCESSING, GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_PROTEIN_MATURATION, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_PROTEIN_FOLDING, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, PARENT_MTOR_SIGNALING_DN, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, OSMAN_BLADDER_CANCER_DN, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, LAIHO_COLORECTAL_CANCER_SERRATED_DN, KEGG_OTHER_GLYCAN_DEGRADATION

GO Biological Process (2): protein folding (GO:0006457), N-glycan processing (GO:0006491)

GO Molecular Function (4): mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activity (GO:0033925), hydrolase activity, hydrolyzing O-glycosyl compounds (GO:0004553), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

CategoryPathways
Asparagine N-linked glycosylation1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure2
cellular process1
protein maturation1
protein N-linked glycosylation1
glycoprotein biosynthetic process1
hydrolase activity, hydrolyzing O-glycosyl compounds1
hydrolase activity, acting on glycosyl bonds1
catalytic activity1
hydrolase activity1
cytoplasm1
intracellular anatomical structure1

Protein interactions and networks

STRING

713 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
ENGASENGLY1Q96IV0788
ENGASEMAN2C1Q9NTJ4597
ENGASEGYG1P46976541
ENGASEMAN1A1P33908541
ENGASENFE2L1Q14494503
ENGASEFAM89AQ96GI7484
ENGASESPEGQ15772473
ENGASEFUT8Q9BYC5457
ENGASEMGAT1P26572448
ENGASEDDI1Q8WTU0427
ENGASEEIPR1Q53HC9391
ENGASEAP1M2Q9Y6Q5379
ENGASEMAN1B1Q9UKM7376
ENGASEEPYCQ99645373
ENGASEZNF70Q9UC06363

IntAct

8 interactions, top by confidence:

ABTypeScore
GNSCLPXpsi-mi:“MI:0914”(association)0.530
PEMTFABP7psi-mi:“MI:0914”(association)0.350
PLD5MACROH2A1psi-mi:“MI:0914”(association)0.350
GNSIGF2Rpsi-mi:“MI:0914”(association)0.350
EGFRILVBLpsi-mi:“MI:0914”(association)0.350
ENGASEuxuApsi-mi:“MI:0915”(physical association)0.000

BioGRID (10): ENGASE (Affinity Capture-MS), ENGASE (Affinity Capture-RNA), ENGASE (Affinity Capture-MS), ENGASE (Affinity Capture-MS), ENGASE (Affinity Capture-MS), ENGASE (Affinity Capture-RNA), ENGASE (Proximity Label-MS), ENGASE (Proximity Label-MS), ENGASE (Affinity Capture-MS), ENGASE (Affinity Capture-RNA)

ESM2 similar proteins: A0A8C2MDK8, A7SLX5, A7YY46, D3ZEY4, D3ZX08, E9QAM5, O59713, O95822, P0C7A1, P48760, P52333, P52824, Q002B5, Q07071, Q14397, Q15477, Q2KI24, Q2M296, Q2NKY8, Q3SYT1, Q3T7C9, Q3U1Y4, Q3URQ7, Q4R380, Q52L34, Q567W6, Q568Y2, Q5I0I8, Q5NCQ5, Q5ZHX9, Q6GPQ5, Q6NZR5, Q6P5E8, Q8BUI3, Q8BX80, Q8C9A2, Q8NFF5, Q8NFI3, Q91X44, Q920F5

Diamond homologs: A1L251, F4JZC2, P0C7A1, Q8BX80, Q8NFI3, Q9SRL4, P60827, Q3T1I2, Q5XIG2, Q6IR41, Q9BXI9, Q9BXJ1, Q9QXP7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

171 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance131
Likely benign10
Benign3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2474 predictions. Top by Δscore:

VariantEffectΔscore
17:79075038:G:GTdonor_gain1.0000
17:79075047:G:GTdonor_gain1.0000
17:79075084:G:GTdonor_gain1.0000
17:79075084:G:Tdonor_gain1.0000
17:79075088:G:GTdonor_gain1.0000
17:79077404:A:AGacceptor_gain1.0000
17:79077405:A:Gacceptor_gain1.0000
17:79077407:T:Gacceptor_gain1.0000
17:79077412:A:AGacceptor_gain1.0000
17:79077413:A:Gacceptor_gain1.0000
17:79077428:A:AGacceptor_gain1.0000
17:79077429:G:GAacceptor_gain1.0000
17:79077429:GC:Gacceptor_gain1.0000
17:79077655:C:Aacceptor_gain1.0000
17:79077656:G:Aacceptor_gain1.0000
17:79077661:A:AGacceptor_gain1.0000
17:79077662:G:GGacceptor_gain1.0000
17:79077717:T:TAacceptor_gain1.0000
17:79077860:GACAG:Gdonor_gain1.0000
17:79077865:G:GAdonor_loss1.0000
17:79077865:G:GGdonor_gain1.0000
17:79079636:GG:Gdonor_gain1.0000
17:79079637:GG:Gdonor_gain1.0000
17:79080197:A:AGacceptor_gain1.0000
17:79080198:T:Gacceptor_gain1.0000
17:79080202:CACAG:Cacceptor_loss1.0000
17:79080203:A:AGacceptor_gain1.0000
17:79080203:ACAG:Aacceptor_gain1.0000
17:79080203:ACAGG:Aacceptor_gain1.0000
17:79080204:C:Gacceptor_gain1.0000

AlphaMissense

4797 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
17:79079562:T:CF164L0.995
17:79079564:C:AF164L0.995
17:79079564:C:GF164L0.995
17:79080335:T:AW232R0.994
17:79080335:T:CW232R0.994
17:79083062:T:CF361L0.994
17:79083064:T:AF361L0.994
17:79083064:T:GF361L0.994
17:79082019:T:CF332L0.993
17:79082021:T:AF332L0.993
17:79082021:T:GF332L0.993
17:79079598:T:AW176R0.992
17:79079598:T:CW176R0.992
17:79079611:C:AA180D0.990
17:79079637:G:TG189W0.990
17:79083074:T:AW365R0.989
17:79083074:T:CW365R0.989
17:79079565:A:CS165R0.988
17:79079567:C:AS165R0.988
17:79079567:C:GS165R0.988
17:79081009:T:AW270R0.988
17:79081009:T:CW270R0.988
17:79081941:T:AW306R0.988
17:79081941:T:CW306R0.988
17:79083486:T:AW383R0.988
17:79083486:T:CW383R0.988
17:79080351:A:TE237V0.987
17:79080346:C:AN235K0.986
17:79080346:C:GN235K0.986
17:79080352:G:CE237D0.986

dbSNP variants (sampled 300 via entrez): RS1000197380 (17:79075982 G>A), RS1000225133 (17:79081369 G>T), RS1000225424 (17:79078570 G>A,T), RS1000448258 (17:79089088 G>A), RS1000728670 (17:79088904 T>C), RS1000830631 (17:79079759 C>T), RS1000991974 (17:79083403 T>A,G), RS1001014099 (17:79087606 G>GA,GC), RS1002110392 (17:79074813 G>C), RS1002141790 (17:79074632 T>C), RS1002161537 (17:79076615 T>G), RS1002353326 (17:79084170 T>G), RS1002691182 (17:79082414 G>A), RS1002722153 (17:79074670 CTGGACTCATAGCCAATGATGGGCAACA>C), RS1002753101 (17:79078055 C>G)

Disease associations

OMIM: gene MIM:611898 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

StudyTraitp-value
GCST009391_1544Metabolite levels2.000000e-06
GCST009391_314Metabolite levels6.000000e-06

EFO canonical traits (2, from GWAS)

EFO IDTrait name
EFO:0010511niacinamide measurement
EFO:0010430triacylglycerol 56:3 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5172 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

5 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 92,872 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL1201863DEXLANSOPRAZOLE41,583
CHEMBL1219RABEPRAZOLE412,441
CHEMBL1503OMEPRAZOLE452,284
CHEMBL480LANSOPRAZOLE424,317
CHEMBL1475252TENATOPRAZOLE22,247

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 10 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
9.03Ki0.925nMNAGSTATIN
8.90Ki1.25nMPOCHONICINE
8.74IC501.83nMNAGSTATIN
8.62IC502.39nMPOCHONICINE
6.38IC50420nMCHEMBL259756
5.35IC504470nMRABEPRAZOLE

PubChem BioAssay actives

6 with measured affinity, of 63 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
2-[(5R,6S,7R,8S)-8-acetamido-6,7-dihydroxy-5-(hydroxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl]acetic acid453057: Competitive inhibition of human placenta beta-N-acetylglucosaminidase by pNP-GlcNAc substrate hydrolysis assayki0.0009uM
N-[[(1R,2S,3S,5S,7R,8S)-1,2,7-trihydroxy-5-(hydroxymethyl)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-3-yl]methyl]acetamide453052: Mixed type inhibition of human placenta beta-N-acetylglucosaminidase by pNP-GlcNAc substrate hydrolysis assayki0.0013uM
(2S,3S,4S,5S,6R)-2-[[(2R,3S,4S,5S,6S)-6-[[(2R,3R,4S,5S,6S)-6-[[(2R,3R,4S,5S,6S)-6-[[(3aS,5R,6S,7R,7aR)-7-hydroxy-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-6-yl]oxy]-4-[(2S,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]methoxy]-4-[(2S,3S,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol318993: Inhibition of human endo-beta-N-acetylglucosaminidase expressed in Hek293 cells after 3 minsic500.4200uM
Rabeprazole1453445: Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysisic504.4700uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
bisphenol Adecreases expression, decreases methylation2
sodium arsenitedecreases expression2
aristolochic acid Iincreases expression1
FR900359increases phosphorylation1
2,4,6-tribromophenoldecreases expression1
methylmercuric chloridedecreases expression1
deoxynivalenolincreases expression1
decabromobiphenyl etherdecreases expression1
beta-lapachonedecreases expression1
perfluorooctanoic aciddecreases expression1
benzo(e)pyreneincreases methylation1
aflatoxin B2increases methylation1
perfluorooctane sulfonic aciddecreases expression1
perfluorohexanesulfonic aciddecreases expression1
abrineincreases expression1
2,2’,4,4’-tetrabromodiphenyl etherdecreases expression1
licochalcone Bincreases expression1
jinfukangaffects cotreatment, increases expression1
PCI 5002affects cotreatment, increases expression1
Arsenicaffects methylation1
Benzo(a)pyreneincreases methylation1
Cisplatinaffects cotreatment, increases expression1
Methapyrileneincreases methylation1
Smokedecreases expression1
Testosteronedecreases expression1
Tobacco Smoke Pollutiondecreases expression1
Zincaffects cotreatment, increases expression1
Aflatoxin B1increases methylation1
Antirheumatic Agentsincreases expression1
Cadmium Chloridedecreases expression1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL1041612BindingInhibition of human placenta beta-N-acetylglucosaminidase by pNP-GlcNAc substrate hydrolysis assayPochonicine, a polyhydroxylated pyrrolizidine alkaloid from fungus Pochonia suchlasporia var. suchlasporia TAMA 87 as a potent beta-N-acetylglucosaminidase inhibitor. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 79

This page pulls from 79 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot